Cambridge Investment Research Advisors, Inc. Gain Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 54,500 shares of GANX stock, worth $145,515. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,500Holding current value
$145,515% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
30Shares Held
2.69MCall Options Held
5.7KPut Options Held
10.6K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.57 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.51 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$714,0140.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA177KShares$472,7900.0% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny158KShares$422,2730.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $31.7M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...